Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of subcutaneous efgartigimod with rHuPH20 in healthy adult men
NL-OMON48123Phase 1Active, not recruiting
- Sponsor
- argenx
- Start
- Jul 2019
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa and ENHANZE in immune thrombocytopenia (ITP) and myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Pharmacodynamics. Started Jul 2019; status: active, not recruiting.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
immune thrombocytopenia (ITP)myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON48123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48123.